Nikoletta Lendvai

US Patent:

20210330254, Oct 28, 2021

Filed:

Apr 21, 2021

Appl. No.:

17/235974

Inventors:

- Horsham PA, US
William DERAEDT - Schelle, BE
Erin C. LEE - Yardley PA, US
Nikoletta LENDVAI - West Windsor NJ, US
Maria Marquez de MONDELO - Belle Mead NJ, US

International Classification:

A61B 5/00
A61B 5/11
A61B 5/16
G16H 20/40

Abstract:

Systems for assessing and documenting changes in handwriting neurologic toxicity adverse events associated with a medical treatment (e.g., immune effector cell therapy) comprise a handwriting neurotoxicity grading criteria that defines the symptoms of at least one adverse event including micrographia, dysgraphia and agraphia. The handwriting neurotoxicity grading criteria may be included in a system for assessing immune effector cell associated movement and neurocognitive disorder, that comprises grading criteria for one or more of the symptom domains: handwriting impairment, gait impairment, other movement abnormalities of extremities, impairment in ability to perform ADLs, and impairment in expression or motivation.